Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Inks Deal To Develop Anti-Obesity Drugs With LG Life Sciences

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement is one of three announced by Takeda March 30, including a deal to develop cancer compounds with CanBas.

You may also be interested in...



Takeda To Help Develop Lundbeck's First-In-Class Mood Disorder Candidates In Japan, U.S.

Takeda Pharmaceutical has taken a step to round out its pipeline by adding mood and anxiety disorder candidates under an agreement with Danish pharma H. Lundbeck

Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.

Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.

Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.

Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.

Related Content

Topics

UsernamePublicRestriction

Register

PS065838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel